Product Information
KT182 is a potent and selective CB1 receptor antagonist that has been shown to inhibit the hydrolysis of 2-arachidonoylglycerol (2-AG) by blocking the binding of fatty acids to the enzyme monoacylglycerol lipase (MAGL). It also blocks some of the effects of endocannabinoids, such as inhibition of microglia and nitrogen atoms. KT182 has been tested in animal studies for metabolic disorders, with promising results. This drug is not orally active and must be administered intravenously. KT182 may be useful for treating obesity, type II diabetes, and other metabolic disorders.
Chemical properties
Technical inquiry about: 3D-CGC61262 KT182
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
